Form 4: Baker Bros. Advisors LP Acquires VTVT Stock Options

Baker Bros. Advisors LP, through its associated entities and individuals, has acquired 6,000 non-qualified stock options for vTv Therapeutics Inc. (VTVT) as part of director compensation.

Summary

• Baker Bros. Advisors LP, along with affiliated entities 667, L.P. and Baker Brothers Life Sciences LP, and individuals Julian C. Baker and Felix J. Baker, are reporting the acquisition of 6,000 non-qualified stock options for vTv Therapeutics Inc. (VTVT).
• These options were granted to Dr. Raymond Cheong, an employee of Baker Bros. Advisors LP and a director of vTv Therapeutics Inc., on June 26, 2026.
• The stock options have an exercise price of $35.08 per share and are set to expire on June 26, 2036.
• Vesting is scheduled for June 26, 2027, or the 2027 annual general meeting, contingent upon Dr. Cheong's continued service on the board.
• The reporting persons are considered directors by deputization due to their representation on the board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard director compensation mechanism rather than a significant strategic or financial event.

Positives

• Grant of stock options to a director, indicating alignment of incentives between management and the company.
• The options are exercisable, providing potential future value to the holder.

Negatives

• The exercise price of $35.08 is significantly higher than the current market price of VTVT, suggesting the options may not be immediately in-the-money.
• The reporting is complex, involving multiple affiliated entities and individuals, which can obscure direct beneficial ownership.

Risks

• The value of the stock options is directly tied to the future performance of vTv Therapeutics Inc.'s stock price, which is subject to market volatility and company-specific risks.
• Contingent vesting based on continued service means the options could be forfeited if Dr. Cheong's directorship ends before the vesting date.

Future Outlook

The future outlook for the stock options is dependent on vTv Therapeutics Inc.'s stock performance and Dr. Cheong's continued service on the board. The options expire in 2036.

Management Comments

• Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP, is a director of vTv Therapeutics Inc. (the "Issuer").
• By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice across the biotechnology and pharmaceutical sectors to incentivize leadership and align their interests with shareholders. The specific strike price and vesting schedule are critical factors in assessing the potential value and motivation behind such grants.

Management Changes

Related Party Transactions

• The acquisition of stock options by Dr. Raymond Cheong, an employee of Baker Bros. Advisors LP, for his role as a director of vTv Therapeutics Inc.

Stakeholder Impact

• Shareholders: The issuance of stock options dilutes existing share ownership, but also aligns director incentives with long-term company performance.
• Employees: Dr. Cheong, as an employee of Baker Bros. Advisors LP, is receiving compensation tied to the company's performance.
• Management: The grant reinforces the relationship between the investment advisor and the company's board.

Next Steps

• Dr. Cheong must remain in service until the vesting date to exercise the stock options.
• The reporting persons will continue to report any further changes in beneficial ownership.

Key Dates

Keywords

VTVT, Form 4, Stock Options, Director Compensation, Baker Bros. Advisors LP, vTv Therapeutics Inc., Beneficial Ownership, Securities Exchange Act